MAS Aggressive

Nearly three in every ten dollars sits in New Zealand or Australian shares, a tilt so heavy it makes this fund the most domestically concentrated of the high-growth options on the market. The portfolio holds $277 million and pushes 95% into growth assets, with international shares taking the remaining two-thirds and a sliver in bonds and cash rounding out the edges.

Fisher & Paykel Healthcare leads at 4.6%, followed by Infratil at 4.4%, then a cluster of New Zealand infrastructure and energy names including Auckland Airport and Meridian. The international side leans into US tech: NVIDIA at 3.1%, Apple at 2.6%, Alphabet and Micron both above 1.8%. The home bias is deliberate and stark, a bet on the performance of local blue chips in a fund otherwise built for long time horizons and high volatility.

Over one year it returned 13.4% and ranked 10th in its category. Over three years the annualised return lifted to 15.2%, placing it 7th, while the five-year figure of 8.2% a year put it 8th. Total fees sit at 0.99%, made up of a 0.87% management charge and 0.1% in other costs, with no performance fee. The fund is managed by Medical Assurance Society, a member-owned organisation with roots in the health sector.

General information only, not financial advice. Past performance is not a reliable indicator of future results.